Blogs

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

In this Q&A blog, BIA spoke to Natasha Gray, Associate & Life Sciences Advisory Service Lead at Warn, a new BIA member.

UK life sciences take centre stage at BIO following a promising Spending Review.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares his insights on BIA's recent Start-up Festival.

An experienced clinician scientist and surgery consultant, Dr Gianmarco Contino brings deep expertise in gastrointestinal cancers and cancer genomics.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

In this blog, Kate Barclay, Skills Consultant at BIA, introduces Skills England, a new Executive Agency within the Department for Education.

At BIA’s recent Start-up festival, we caught up with Mark Bartlett, CEO of StoreGene, to learn more about his journey, what drives him, and his advice for founders navigating the world of genomics and startups.

In this blog Richard Turner, the new vice chair of FTAC, examines the UK's overhauled R&D tax regime, which provides competitive incentives and a stable fiscal framework.

Pension capital is unlocked in time for BIA's Parliament Day this Wednesday.

The Mansion House Accord signed on 13 May and the publication of the Government’s Pensions Investment Review mark the latest developments in the BIA’s campaign to unlock pension funds for life sciences. Here, our Director of Policy and External Affairs, Dr Martin Turner, reflects on how we got to this point and what must happen next.

Karen Johal, Senior Director at FTI Consulting LLP, explores how salary sacrifice for pensions offers a smart solution to rising employment costs - helping employers cut costs without cutting staff.

In this blog, Nick Hutchinson, Associate Vice President of Just-Evotec Biologics, provides insight into their new fully continuous end-to-end manufacturing platform while also giving inspiration to young scientists.

We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar. 

The UK attracts global investment and strengthens its key institutions while start-up CEOs tap into the new BIA guide to accelerator programmes.

WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.

The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.

In this blog, Vector Bioscience Cambridge's CEO and Co-Founder, Lluna Gallego, outlines the past, present and future of the company.

The Mansion House Accord fails to sparkle, but as the UK and EU reset relations, our focus turns to opportunities in deep biotech and the need for migration policy to support the talent our sector needs to thrive.